Vulnerable subjects, including systemic lupus erythematosus (SLE) patients, have been
prioritised to receive anti-SARS-CoV-2 vaccines. Few data about the safety of these …

Tuberculosis risk is increased in patients with chronic inflammatory diseases receiving any
immunosuppressive treatment, notably tumor necrosis factor (TNF) antagonists therapy …

Objectives To determine the association between neutrophil to lymphocyte ratio (NLR) and
platelet to lymphocyte ratio (PLR) with disease activity and flares in an inception cohort of …

Background: Data on serum antibodies in untreated adult inflammatory bowel disease (IBD)
patients at diagnosis are scarcely available, and results on the stability of antibody presence …

Persistent exposure of the immune system to death cell debris leads to autoantibodies
against chromatin in patients with systemic lupus erythematosus (SLE). Deposition of anti …

Objectives To determine the presence and clinical associations of the soluble receptors of B
cell‐activating factor from the tumor necrosis factor family (BAFF) in serum of patients with …

B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) help in B cell
activation, maintenance and plasma cell survival. B cell infiltration has been demonstrated in …

Objective Disease activity monitoring in SLE includes serial measurement of anti-double
stranded-DNA (dsDNA) antibodies, but in patients who are persistently anti-dsDNA positive …

Introduction Patients with systemic lupus erythematosus (SLE) with B-lymphocyte stimulator
(BLyS) levels≥ 2 ng/mL are at increased risk of flare. A regression analysis was undertaken …

Immune dysregulation in systemic lupus erythematosus (SLE) contributes to increased
disease activity. African-American (AA) SLE patients have an increased prevalence of …